Pyrazidol® [Pirlindole]
Pharmstandard
1650 Items
2019-09-19
- done All payments are SSL encrypted
- done Full Refund if you haven't received your order
- done International shipping to the USA, UK and Europe
Clinical Pharmacology
Pyrazidol - thymoleptic, antidepressant.
Selectively inhibits type A MAO, blocks deamination of serotonin and norepinephrine, and to a lesser extent, tyramine. Partially inhibits monoamine reuptake, potentiates the effects of norepinephrine precursor - dioxyphenylalanine (L-DOPA) and serotonin precursor - 5-hydroxytryptophan. Stimulates adreno-and serotoninergichesky structures. It activates the processes of synaptic transmission of nervous excitation in the central nervous system. It has a nootropic effect, improves cognitive function.
Pharmacodynamics
Thymoleptic effect is combined with a balanced effect on the central nervous system (activating effect in patients with apathetic, anergic depressions or a sedative effect in patients in the agitated state).
Indications
Depression, incl. senile, involutional, occurring predominantly with psychomotor retardation and asthenic disorders, anxiety-depressive or anxious-delusional components, alcohol withdrawal syndrome, Alzheimer's disease (as part of complex therapy).
Composition
Active substance: Pirlindole;
Excipients: milk sugar; potato starch; calcium stearate
No customer reviews for the moment.
Dosage and Administration
For oral use, at 0.05–0.075 g / day in 2 divided doses, gradually increasing the dose by 0.025–0.05 g to 0.15–0.30 g / day. The maximum daily dose is 0.4 g divided into 2–3 doses. After achieving a therapeutic effect, treatment is continued for 2-4 weeks, after which the dose is gradually reduced.
Adverse reactions
Dry mouth, nausea, sweating, hand tremor, tachycardia, dizziness, allergic reactions.
Contraindications
Hypersensitivity, acute hepatitis, blood diseases, simultaneous administration of MAO inhibitors.
Drug interactions
Increases the effectiveness of epinephrine (due to anti-monoamine oxidase activity). Compatible with antipsychotics, anxiolytics. Incompatible with antidepressants - MAO inhibitors, furazolidone, procarbazine, selegiline.
Pregnancy and Lactation
Adequate and strictly controlled studies on the safety and efficacy of the drug during pregnancy and lactation have not been conducted.
Special instructions
Pyrazidol is not prescribed simultaneously with MAO antidepressant inhibitors, furazolidone, procarbazine, selegiline.
Perhaps the use of pyrazidol in patients with glaucoma and benign prostatic hyperplasia.
Pirazidol is compatible with antipsychotics, anxiolytics.
- Brand name: Pyrazidol
- Active ingredient: Pirlindole
- Dosage form: pills
- Manufacturer: Pharmstandard
- Country of Origin: Russia
Studies and clinical trials of Pirlindole (Click to expand)
- Double-Blind Randomized Controlled Pilot Study of the Efficacy and Tolerability of Pirlindole, a Reversible Inhibitor of Monoamine Oxidase A, and Mianserin, in the Treatment of Depression
- ChemInform Abstract: First Preparative Enantiomer Resolution of Pirlindole, a Potent Antidepressant Drug.
- ChemInform Abstract: Inhibition of Monoamine Oxidase by Pirlindole Analogues: 3D-QSAR and CoMFA Analysis.
- ChemInform Abstract: Domestic Antidepressants: Part 2. Pyrazidole (Pirlindole)
- Persistence of central effects of pirlindole, a short-acting monoamineoxidase inhibitor, in the presence of a monoamineoxidase inhibitor
- Determination of pirlindole in plasma and urine by high-performance liquid chromatography
- Automated determination of pirlindole enantiomers in plasma by on-line coupling of a pre-column packed with restricted access material to a chiral liquid chromatographic column
- Simultaneous determination of pirlindole enantiomers and dehydropirlindole by chiral liquid chromatography
- Enantiomeric separation of pirlindole by liquid chromatography using different types of chiral stationary phases
- Effects of the antidepressant pirlindole and its dehydro-derivative on the activity of monoamine oxidase-a and on GABAAreceptors
- Pirlindole and dehydropirlindole protect rat cultured neuronal cells against oxidative stress-induced cell death through a mechanism unrelated to MAO-A inhibition
- Domestic Antidepressants. 2. Pyrazidole (Pirlindole)
- Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure
- Pre- and post-treatment with pirlindole and dehydropirlindole protects cultured brain cells against nitric oxide-induced death
- Preparative resolution of racemic pirlindole: Chromatrographic methods and determination of the absolute configuration: P. de Tullio∗, A. Ceccato$, J.-F. Liégeois∗, B. Pirotte∗, A. Felikidis∗, M. Stachow∗, P. Hubert$, J. Crommen$, J. Géczy£, J. Delarge∗. ∗ Deparment of Medicinal Chemistry, University of Liège, 3 rue Fusch, B-4000 Liège, Belgium. $ Department of Drug Analysis, University of Liège, Avenue de l'Hôpital, B-4000 Liège-1, Belgium. £ Therabel Research, 110 rue Egide van Ophem, B-1180 Bruxelles, Belgium
- A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression
- Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression
- First Preparative Enantiomer Resolution of Pirlindole, a Potent Antidepressant Drug
- PIRLINDOLE: A SELECTIVE REVERSIBLE INHIBITOR OF MONOAMINE OXIDASE A. A REVIEW OF ITS PRECLINICAL PROPERTIES
- Pirlindole in the Treatment of Depression
- Pirlindole in the Treatment of Depression and Fibromyalgia Syndrome
- Inhibition of Monoamine Oxidase by Pirlindole Analogues: 3D-QSAR and CoMFA Analysis
- Efficacy of Pirlindole, a Highly Selective Reversible Inhibitor of Monoamine Oxidase Type A, in the Prevention of Experimentally Induced Epileptic Seizures
Customers who bought this product also bought:
8 other products in the same category:
arrow_upward